Early Line Dominance of Teva's Copaxone and Biogen Idec's Avonex in the Treatment of Multiple Sclerosis To Diminish Following the Launch of Oral Disease-Modifying Therapies

Monday, April 19, 2010 General News
Email Print This Page Comment
Font : A-A+

However, Half of Surveyed Neurologists Do Not Expect to Change Their Prescribing Habits of Copaxone or IFN-beta Therapies by 2012, According to a New Report from Decision Resources

Decision Resources

Decision Resources, Inc.

Lisa Osgood

Chris Comfort

781-296-2606

781-296-2597

losgood@hl-isy.com

ccomfort@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook